Evidence map›Paper›PMID 35831643›Full record

ArticleInflammation2022

Piperlongumin Improves Survival in the Mouse Model of Sepsis: Effect on Coagulation Factors and Lung Inflammation.

Zhendong Fang, Xianwei Zhang, Yueyue Huang, Hongmin Zhou, Yilun Lu, Yuanyuan Sun, Fanrong Ye, Songzan Qian, Lingling Pan, Wenjing Chen and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Inflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Platelet P2YBritish journal of pharmacology · 2024
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Zhendong FangDepartment of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Xianwei ZhangDepartment of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yueyue HuangDepartment of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Hongmin ZhouDepartment of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yilun LuDepartment of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yuanyuan SunDepartment of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Fanrong YeDepartment of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Songzan QianDepartment of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Lingling PanDepartment of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Wenjing ChenDepartment of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Hao JiangDepartment of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Jingye PanDepartment of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. wmupanjingye@126.com.
Wenzhou University · CNFirst Affiliated Hospital of Wenzhou Medical University · CNWenzhou Medical University · CN

Funding

Major Science and Technology Project of Wenzhou Science and Technology Bureau 2018ZY002National Natural Science Foundation of China 81671968the Major project co-founded by Zhejiang Province and Ministry of Science and Technology WKJ-ZJ-1909the Medical Innovation Discipline of Zhejiang Province Critical Care Medicine, Y2015The Project of Public Innovation Platform and Carrier in Zhejiang Province 2021E10016Wenzhou Key Technology Breakthrough Program on Prevention and Treatment for COVID-19 Epidemic, Wenzhou Science and Technology Bureau ZG2020012
6 · The paper itself

Abstract

Excessive inflammation and coagulation contribute to high morbidity and mortality in sepsis. Many studies have indicated the role of piperlongumine (PL) in anti-inflammation, but its effect on coagulation remains uncertain. Here, we explore whether PL could moderate coagulation indicators and alleviate lung inflammation during sepsis. RAW264.7 cells were induced by lipopolysaccharide (LPS) and treated with PL. Inflammatory and coagulation indicators, cell function and signaling, were evaluated in cells. Cecal ligation and puncture (CLP) mice were treated with PL by gavage. The harvested lungs and plasma were used to assess inflammation and coagulation indicators. As a result, PL increased the survival rate and reduced the concentrations of tissue factor (TF), plasminogen activator inhibitor 1 (PAI-1), thrombin-antithrombin complex (TAT), D-dimer, interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF)-α in CLP mice, with fibrinogen in reverse. Moreover, the PL alleviated inflammation, fibrin deposition, and lung injury in the lungs of CLP mice. In vitro, PL downregulated the expression of TF, PAI-1, IL-6, TNF-α, and IL-1β in RAW264.7 cells induced by LPS. Furthermore, PL inhibited the phosphorylation of the AKT/mTOR signaling pathway's key proteins and suppressed the nuclear translocation of p-STAT3 in LPS-stimulated RAW264.7 cells. In conclusion, this study suggests that PL may modulate coagulation indicators and improve lung inflammation through AKT/mTOR signaling pathway in sepsis.

Indexed as

PneumoniaSepsisAnimalsDisease Models, AnimalInflammationInterleukin-6LipopolysaccharidesLungMicePlasminogen Activator Inhibitor 1Proto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesTumor Necrosis Factor-alphaInterleukin-6LipopolysaccharidesPlasminogen Activator Inhibitor 1Proto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesTumor Necrosis Factor-alphaAKT/mTOR.coagulation indicatorslung inflammationpiperlonguminesepsis

Identifiers

PMID35831643
PMCPMC9281243
OpenAlexW4285083790

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.